<DOC>
	<DOC>NCT00047554</DOC>
	<brief_summary>The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension. To be eligible for the study, these individuals must have experienced an iris pigmentation change while previously dosing with TRAVATAN.</brief_summary>
	<brief_title>Study of TRAVATAN in Subjects With Iris Pigmentation Changes</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Inclusion: ï»¿Diagnosis of openangle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension; Has experienced an iris pigmentation change while dosing with TRAVATAN; Currently dosing with TRAVATAN; Other protocoldefined inclusion criteria may apply. Exclusion: Any form of glaucoma other than openangle glaucoma (with or without a pigment dispersion or pseudoexfoliation component) or ocular hypertension; Not currently using TRAVATAN; Females of childbearing potential if pregnant, breastfeeding, or not using highly effective birth control measures; History of any severe ocular pathology (including severe dry eye); Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>open-angle</keyword>
	<keyword>glaucoma</keyword>
	<keyword>ocular</keyword>
	<keyword>hypertension</keyword>
	<keyword>primary open-angle glaucoma</keyword>
	<keyword>iris</keyword>
	<keyword>pigmentation</keyword>
</DOC>